BioXcel Therapeutics announces publication on active ingredient in BXCL-501

BioXcel Therapeutics (BTAI) announced a publication in the peer-reviewed journal Frontiers in Pharmacology, entitled “Dexmedetomidine potently and reversibly regulates stress-mediated behaviors.” The study demonstrated a significant effect in translatable behavioral models related to psychiatric disorders suggesting potential applications of BXCL501 in chronic conditions in addition to treatment of acute agitation. BXCL501 has already been clinically validated and FDA approved for treatment of acute episodes of agitation associated with bipolar disorder or schizophrenia. Dexmedetomidine, an alpha2-adrenergic receptor agonist, is the active ingredient in BXCL501. The published results provide further support for the drug’s mechanism of action and potential suitability for broadly addressing stress-related disorders in addition to agitation.